Cargando…

Disseminated intravascular coagulation observed following treatment with gemtuzumab ozogamicin for relapsed/refractory acute promyelocytic leukemia

Gemtuzumab ozogamicin (GO) is a recombinant humanized immunoglobulin G4 anti-cluster of differentiation (CD)33 monoclonal antibody conjugated to N-acetyl-γ calicheamicin dimethylhydrazide, a naturally potent antibiotic. It has been introduced for the treatment of acute promyelocytic leukemia (APL),...

Descripción completa

Detalles Bibliográficos
Autores principales:	AZUMA, YOSHIKO, NAKAYA, AYA, HOTTA, MASAAKI, FUJITA, SHINYA, TSUBOKURA, YUKIE, YOSHIMURA, HIDEAKI, SATAKE, ATSUSHI, ISHII, KAZUYOSHI, ITO, TOMOKI, NOMURA, SHOSAKU
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2016
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4906953/ https://www.ncbi.nlm.nih.gov/pubmed/27330760 http://dx.doi.org/10.3892/mco.2016.864

Ejemplares similares

Enhanced international prognostic index in Japanese patients with diffuse large B-cell lymphoma
por: Nakaya, Aya, et al.
Publicado: (2016)

Clinical significance of dasatinib-induced pleural effusion in patients with de novo chronic myeloid leukemia
por: Nakaya, Aya, et al.
Publicado: (2018)

Impact of CRAB Symptoms in Survival of Patients with Symptomatic Myeloma in Novel Agent Era
por: Nakaya, Aya, et al.
Publicado: (2017)

A variant of acute promyelocytic leukemia with t(4;17)(q12;q21) showed two different clinical symptoms
por: Nakanishi, Takahisa, et al.
Publicado: (2019)

Transplant-Ineligible Symptomatic but Indolent Multiple Myeloma Shows Better Prognosis with Conventional Agents
por: Nakaya, Aya, et al.
Publicado: (2017)

Dasatinib-induced hemorrhagic colitis complicated with cytomegalovirus infection
por: Nakaya, Aya, et al.
Publicado: (2017)

Secondary pure red cell aplasia in multiple myeloma treated with lenalidomide
por: Ito, Tomoki, et al.
Publicado: (2018)

Blastic Epstein-Barr virus associated post-transplant lymphoproliferative disorder after allogeneic stem cell transplantation for severe aplastic anemia
por: Hotta, Masaaki, et al.
Publicado: (2018)

Combined Use of Ninjin'yoeito Improves Subjective Fatigue Caused by Lenalidomide in Patients With Multiple Myeloma: A Retrospective Study
por: Ito, Tomoki, et al.
Publicado: (2018)

Human T-cell Leukemia Virus Type I Associated with an Increased Risk of Primary Malignant Neoplasm
por: Nakaya, Aya, et al.
Publicado: (2018)

Myodesopsia is a symptom of central nervous system blast crisis in chronic myeloid leukemia
por: Ishii, Kazuyoshi, et al.
Publicado: (2019)

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
por: Takeyasu, Yuki, et al.
Publicado: (2017)

Evaluation of eltrombopag in patients with aplastic anemia in real-world experience
por: Konishi, Akiko, et al.
Publicado: (2019)

Neutrophil-to-lymphocyte ratio (NLR) fails to predict outcome of diffuse large B cell lymphoma
por: Azuma, Yoshiko, et al.
Publicado: (2019)

Retrospective analysis of adolescent and young adult with lymphoma at two cancer facilities in Japan
por: Nakaya, Aya, et al.
Publicado: (2019)

Evaluation of azacitidine in patients with transplant-ineligible myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes in a Japanese clinical setting
por: Nakaya, Aya, et al.
Publicado: (2020)

Trend of salvage treatment in diffuse large B cell lymphoma in the outpatient chemotherapy era
por: Nakaya, Aya, et al.
Publicado: (2019)

Mogamulizumab treatment of refractory peripheral T-cell lymphoma following autologous stem cell transplantation: A case report
por: FUJITA, YUKIE, et al.
Publicado: (2016)

Gemtuzumab Ozogamicin: Back Again
por: Selby, Chris, et al.
Publicado: (2019)

Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan
por: Yoshimura, Hideaki, et al.
Publicado: (2017)

Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma
por: Nomura, Shosaku, et al.
Publicado: (2018)

Gemtuzumab ozogamicin: Various toxicities: 2 case reports
Publicado: (2017)

Therapeutic Targeting of Acute Myeloid Leukemia by Gemtuzumab Ozogamicin
por: Gottardi, Michele, et al.
Publicado: (2021)

Early administration of lenalidomide after allogeneic hematopoietic stem cell transplantation suppresses graft‐versus‐host disease by inhibiting T‐cell migration to the gastrointestinal tract
por: Tsubokura, Yukie, et al.
Publicado: (2022)

Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment
por: Fenwarth, Laurène, et al.
Publicado: (2020)

Pharmacokinetic/Pharmacodynamic Modeling to Support the Re‐approval of Gemtuzumab Ozogamicin
por: Fostvedt, Luke K., et al.
Publicado: (2019)

Update on the role of gemtuzumab-ozogamicin in the treatment of acute myeloid leukemia
por: Swaminathan, Mahesh, et al.
Publicado: (2023)

Six cases of autoimmune acquired coagulation factor VIII deficiency: Single center experience in Japan
por: Konishi, Akiko, et al.
Publicado: (2020)

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Duong, Hien K, et al.
Publicado: (2009)

Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Pulmonary and Kidney Failure
por: Zaytsev, Daniil, et al.
Publicado: (2020)

MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
por: Fultang, Livingstone, et al.
Publicado: (2019)

Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin
por: Lamba, Jatinder K., et al.
Publicado: (2021)

Multiple Myeloma with Central Nervous System Relapse Early after Autologous Stem Cell Transplantation: A Case Report and Literature Review
por: Hotta, Masaaki, et al.
Publicado: (2021)

Refractory Chronic Lymphocytic Leukemia with Central Nervous System Involvement: A Case Report with Literature Review
por: Nakanishi, Takahisa, et al.
Publicado: (2020)

Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin
por: Kurimoto, M, et al.
Publicado: (2013)

Clinical and experimental efficacy of gemtuzumab ozogamicin in core binding factor acute myeloid leukemia
por: Gottardi, Michele, et al.
Publicado: (2017)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

AKT Signaling as a Novel Factor Associated with In Vitro Resistance of Human AML to Gemtuzumab Ozogamicin
por: Rosen, David B., et al.
Publicado: (2013)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1h51uvrdee11lnegvjbfocfiku